Silvia Giordano

Q: What Schools Are Affiliated With Silvia Giordano

Silvia Giordano is affiliated with the following schools: University of Palermo, University of Turin, University of Geneva, University of Cagliari

Silvia Giordano's AcademicInfluence.com Rankings

Silvia Giordano

Computer Science

#9855

World Rank

#10338

Historical Rank

Database

#6805

World Rank

#7044

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Silvia Giordano's Degrees

PhD Computer Science University of Geneva
Masters Computer Science University of Geneva
Bachelors Computer Science University of Geneva

Similar Degrees You Can Earn

Why Is Silvia Giordano Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Silvia Giordano's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (2003) (1296)
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family (1994) (1010)
Drug development of MET inhibitors: targeting oncogene addiction and expedience (2008) (806)
The Dual Roles of NRF2 in Cancer. (2016) (571)
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. (2013) (560)
Expression of the Met/HGF receptor in normal and neoplastic human tissues. (1991) (496)
Tyrosine kinase receptor indistinguishable from the c-met protein (1989) (474)
The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met (2002) (467)
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. (1995) (466)
The Semaphorin 4D receptor controls invasive growth by coupling with Met (2002) (454)
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. (2008) (400)
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. (2005) (376)
MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? (2013) (336)
Negative receptor signalling. (2003) (331)
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas (2000) (327)
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages (2008) (260)
Cancer therapy: can the challenge be MET? (2005) (252)
Sema4D induces angiogenesis through Met recruitment by Plexin B1. (2005) (239)
Biosynthesis of the protein encoded by the c-met proto-oncogene. (1989) (218)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy (2010) (216)
Tumorigenic and metastatic activity of human thyroid cancer stem cells. (2010) (214)
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. (1995) (203)
Interplay between scatter factor receptors and B plexins controls invasive growth (2004) (189)
YAP activation is an early event and a potential therapeutic target in liver cancer development. (2014) (184)
MicroRNAs impair MET-mediated invasive growth. (2008) (183)
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. (2006) (175)
A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation (1997) (171)
Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis (2000) (169)
Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes (1997) (168)
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. (2010) (166)
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. (1991) (165)
Specific Uncoupling of GRB2 from the Met Receptor (1996) (164)
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. (2018) (164)
C-terminal truncated forms of Met, the hepatocyte growth factor receptor (1991) (160)
Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. (1993) (158)
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. (2003) (158)
Plexin‐B3 is a functional receptor for semaphorin 5A (2004) (155)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling (2007) (143)
Met as a therapeutic target in HCC: facts and hopes. (2014) (142)
Hepatocyte growth factor and its receptor are required for malaria infection (2003) (141)
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists (1999) (140)
Silencing the MET oncogene leads to regression of experimental tumors and metastases (2008) (135)
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. (2011) (133)
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. (2011) (133)
Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS) (2006) (133)
Ets up-regulates MET transcription. (1996) (131)
Molecular cancer therapy: can our expectation be MET? (2008) (130)
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer (2011) (127)
Plexin signaling hampers integrin‐based adhesion, leading to Rho‐kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility (2004) (126)
MET overexpression turns human primary osteoblasts into osteosarcomas. (2006) (119)
Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells* (2004) (118)
Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach (2016) (117)
HGF/MET signalling protects Plasmodium‐infected host cells from apoptosis (2005) (110)
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition (2010) (107)
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. (2009) (103)
MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC) (2014) (99)
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. (1998) (96)
Only a subset of Met-activated pathways are required to sustain oncogene addiction. (2009) (94)
A point mutation in the MET oncogene abrogates metastasis without affecting transformation. (1997) (93)
Semaphorin 4D regulates gonadotropin hormone–releasing hormone-1 neuronal migration through PlexinB1–Met complex (2008) (92)
Different point mutations in the met oncogene elicit distinct biological properties (2000) (87)
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. (2013) (80)
Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function1 (2001) (80)
Activation of RAS family members confers resistance to ROS1 targeting drugs (2014) (80)
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis (1999) (79)
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. (2005) (77)
Yes‐associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice (2011) (76)
Nrf2, but not β‐catenin, mutation represents an early event in rat hepatocarcinogenesis (2015) (75)
Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression (2012) (73)
p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line (1988) (73)
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis (2016) (71)
Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. (1992) (69)
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study (2017) (68)
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors (2016) (65)
Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). (1994) (65)
MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. (2014) (65)
TGFα expression impairs Trastuzumab-induced HER2 downregulation (2005) (65)
Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor) (1991) (65)
Targeted therapies for gastric cancer: failures and hopes from clinical trials (2017) (62)
Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. (1990) (60)
Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats (2015) (60)
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC (2017) (59)
Targeted therapies for gastric cancer: failures and hopes from clinical trials. (2017) (56)
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging (2016) (55)
MET receptor is overexpressed but not mutated in oral squamous cell carcinomas (2001) (55)
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib (2011) (54)
How Can Gastric Cancer Molecular Profiling Guide Future Therapies? (2016) (53)
Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response (2015) (52)
Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. (2009) (49)
Structure and inducible regulation of the human MET promoter. (1994) (49)
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies (2018) (47)
By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy (2014) (45)
Microsatellite instability in Gastric Cancer: Between lights and shadows. (2021) (45)
Control of invasive growth by the HGF receptor family (1997) (45)
Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling (2001) (44)
Targeting MET: why, where and how? (2013) (43)
Shedding‐Generated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway (2012) (43)
Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells (1993) (42)
Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum. (1994) (41)
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits. (2019) (39)
Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction (2009) (36)
Methylation analysis of the promoter F of estrogen receptor α gene: effects on the level of transcription on human osteoblastic cells (2004) (33)
Resistance to targeted therapies: a role for microRNAs? (2013) (33)
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming. (2020) (31)
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor (2018) (31)
Human ASH‐1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells (2013) (30)
Expression of the human oestrogen receptor-alpha gene is regulated by promoter F in MG-63 osteoblastic cells. (2003) (28)
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. (2016) (28)
Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor α (2005) (27)
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort (2017) (27)
Clustered protocadherins methylation alterations in cancer (2019) (27)
The c-met/HGF receptor in human tumours (1992) (26)
Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases. (1986) (25)
FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. (2021) (25)
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis (2015) (25)
miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling (2018) (24)
The landscape of d16HER2 splice variant expression across HER2-positive cancers (2019) (24)
Electrostatic Intraperitoneal Aerosol Delivery of Nanoparticles: Proof of Concept and Preclinical Validation (2020) (24)
Semaphorin pathways orchestrate osteogenesis (2006) (22)
Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells (2000) (22)
Downregulating Neuropilin-2 Triggers a Novel Mechanism Enabling EGFR-Dependent Resistance to Oncogene-Targeted Therapies. (2018) (21)
Proteins phosphorylated on tyrosine as markers of human tumor cell lines (1987) (21)
Invasive growth: A two-way street for semaphorin signalling (2004) (21)
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody (2018) (20)
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach (2018) (20)
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells (2003) (20)
CD 100 / Plexin-B 1 interactions sustain proliferation and survival of normal and leukemic CD 5 B lymphocytes (2003) (18)
Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence (2020) (17)
Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas (2020) (17)
Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. (2005) (16)
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence (2014) (16)
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts12 (2018) (15)
Application of 3D Mass Spectrometry Imaging to TKIs (2017) (15)
Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line (1988) (14)
A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging (2017) (13)
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging (2020) (12)
Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases (2020) (12)
Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. (2010) (11)
Erratum: Only a subset of met-activated pathways are required to sustain oncogene addiction (Science Signaling (2009) 2 (er11) (2009) (11)
Distinct Mechanisms Are Responsible for Nrf2-Keap1 Pathway Activation at Different Stages of Rat Hepatocarcinogenesis (2020) (11)
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives (2021) (10)
MiRNAs as new master players (2009) (10)
C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells (1998) (10)
Potential role of two novel agonists of thyroid hormone receptor‐β on liver regeneration (2020) (9)
MicroRNAs: new tools for diagnosis, prognosis and therapy in HCC? (9)
TRANSFER OF THE MOTOGENIC AND INVASIVE RESPONSE TO SCATTER FACTOR HEPATOCYTE GROWTH-FACTOR BY TRANSFECTION OF THE HUMAN C-MET PROTOONCOGENE (1993) (9)
Transcription factor decoy against promoter C of estrogen receptor α gene induces a functional ERα protein in breast cancer cells (2005) (9)
Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness (2001) (9)
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas (2021) (8)
Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review (2020) (8)
Targeting Plasmodium host cells: survival within hepatocytes. (2004) (8)
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3. (2011) (8)
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine (2022) (7)
Drug-Homogeneity Index in Mass-Spectrometry Imaging. (2018) (7)
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas (2022) (7)
Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. (2018) (7)
Molecularly Targeted Therapies for Gastric Cancer. State of the Art (2021) (7)
Targeted therapies in cancer and mechanisms of resistance (2014) (6)
Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells (2020) (6)
MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer (2020) (6)
Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer. (2013) (5)
A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data (2020) (5)
A long term, non-tumorigenic rat hepatocyte cell line and its malignant counterpart, as tools to study hepatocarcinogenesis (2017) (5)
Transcription factor decoy against promoter C of estrogen receptor alpha gene induces a functional ER alpha protein in breast cancer cells. (2005) (5)
Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. (2021) (4)
The importance of being CAFs (in cancer resistance to targeted therapies) (2022) (3)
Non-linear relationship between HER-2 expression and response to trastuzumab in breast cancer cells. (2006) (3)
Personalized therapeutic strategies in HER2-driven gastric cancer (2021) (2)
APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett’s-associated esophageal adenocarcinomas (2022) (2)
Editorial: Metabolism As a Therapeutic Target (2017) (2)
[Malignant mesothelioma of the pleura in a worker with brief atypical exposure to chrysotile asbestos]. (2004) (2)
Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC (2021) (2)
The metabolic gene HAO2 is downregulated in mouse, rat and human hepatocellular carcinoma and correlates with metastasis and poor survival (2016) (2)
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
Mutations of Nrf2 are an early and frequent event in the development of rat hepatocellular carcinoma (2015) (2)
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (2)
Diverse MicroRNAs‐mRNA networks regulate the priming phase of mouse liver regeneration and of direct hyperplasia (2022) (1)
Preclinical activity of two paclitaxel nanoparticle formulations after IP administration in ovarian cancer xenografts (2018) (1)
A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer (2021) (1)
Signaling from Internalized Receptors (2006) (1)
Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy (2019) (1)
The Tyrosine Kinase c-Met Is Selectively Expressed on Motile Hematopoietic Progenitors Following G-CSF Administration and Promotes Mobilization by Regulating Stem Cell Niche Components. (2006) (1)
FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling (2020) (1)
Reply to: "YAP in tumorigenesis: Friend or foe?". (2015) (1)
A chimeric antibody (MV-DN30) inhibiting (2014) (1)
Extensive “halo naevi” phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome? (2022) (1)
Abstract 1009: Metabolic reprogramming discriminates aggressive vs. slowly growing preneoplastic lesions at early stages of HCC development (2016) (1)
Researchof HER family members in gastric carcinoma cells mediates resistance to MET inhibition (2010) (1)
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy (2022) (1)
Potential role of two novel agonists of thyroid hormone receptor-beta on liver regeneration (2020) (1)
Reviewmechanisms of acquired resistance to tyrosine kinase targeted therapy (2010) (1)
Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (0)
Abstract B12: Understanding the role of the tumor microenvironment in mediating resistance to anti-MET drugs (2015) (0)
Combined anti-MET/EGFR treatment results in complete tumor regression and prevents resistance onset in a MET-amplified gastroesophageal xenopatient cohort (2016) (0)
Abstract A82: HHER2‐positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib (2009) (0)
Identification and Localization of Phosphoproteins in v-onc Transformed Fibroblasts by Means of Phosphotyrosine Antibodies (1985) (0)
The HGF/SF receptor kinase: structure and function (1993) (0)
Proteins phosphorylated on tyrosine as markers of human malignancies (1987) (0)
216 MIR-100 IS DOWNREGULATED FROM EARLY STAGES OF HEPATOCARCINOGENESIS AND CORRELATES WITH OVEREXPRESSION OF ITS TARGET PLK1 (2011) (0)
Nanoparticle-based matrixes for imaging mass spectrometry: visualization of drugs distribution in solid tumor tissues (2015) (0)
APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett’s-associated esophageal adenocarcinomas (2022) (0)
Abstract P1-09-21: Clinical evaluation of miR-100 as a predictor of endocrine-responsiveness in hormone-receptor positive breast cancer (2017) (0)
Abstract 3851: Targeting HER2 in gastric cancer: Hints from a gastric PDX platform (2017) (0)
Hepatocyte growth factor/met system (2003) (0)
Ciclo XXVII ROLE OF HYDROXY ACID OXIDASE 2 ( HAO 2 ) (2015) (0)
Abstract 1399: NRF2 mutations are frequent in early rat preneoplastic hepatic lesions and in human hepatocellular carcinomas positive for the stem/progenitor cell marker KRT-19 (2014) (0)
312 MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors (2010) (0)
Identification of a subpopulation of patients with gastric cancer responsive to PARP inhibitors. (2023) (0)
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas (2022) (0)
455 HER2: A target for prostate cancer therapy? (2004) (0)
P59 YES-ASSOCIATED PROTEIN (YAP) IS REQUIRED FOR THE CLONAL EXPANSION OF PRENEOPLASTIC HEPATOCYTES AND OVAL CELL PROLIFERATION (2014) (0)
Interdisciplinar and multidimensional approach in neoplastic aged patients (1997) (0)
Metabolic Reprogramming toward Awarburg Phenotype Characterizes Early Phases of Hepatic Carcinogenesis (2016) (0)
234 ROLE OF YAP IN THE REGULATION OF XENOBIOTIC-INDUCED LIVER ENLARGEMENT AND HCC DEVELOPMENT (2011) (0)
Monocyte-Macrophage Function Hepatocyte Growth Factor Is a Regulator of (2000) (0)
The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients (2022) (0)
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers (2020) (0)
Transcription profiling by array of mouse liver from TCPOBOP treated wild type and c-jun conditional knockout animals. (2012) (0)
Molecular Classification of Gastric Cancer: A New Perspective for Therapy and Prognosis? (2021) (0)
Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (0)
Abstract A04: Combined anti–MET/EGFR treatment results in complete tumor regression and prevents resistance onset in a MET-amplified gastroesophageal xenopatient cohort (2016) (0)
Abstract 622: Gastric cancer in the age of targeted agents: identification and validation of novel therapeutic strategies through the generation of a patient-derived xenografts platform (2016) (0)
671: Inhibition of angiogenesis promotes a homogeneous intra-tumor distribution of chemotherapy associated with better antitumor response (2014) (0)
A nanostructured matrices assessement to study drugs distribution in solid tumor tissues by mass spectrometry imaging (2015) (0)
normal and leukemic CD5+ B lymphocytes CD100/Plexin-B1 interactions sustain proliferation and survival of (2013) (0)
Detection of deregulated tyrosine-kinases in experimental and human metastatic tumors. (1988) (0)
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (0)
hematopoietic progenitor cells via ROS signaling induced mobilization of - Enhanced c-Met activity promotes G-CSF (2011) (0)
P0397 : Nrf2 mutations are an early and frequent event in the development of rat hepatocellular carcinoma (2015) (0)
Stem Cells Tumorigenic and Metastatic Activity of Human Thyroid Cancer (2010) (0)
Cancer esearch apeutics , Targets , and Chemical Biology T and KRAS Gene Amplification Mediates Acquired R istance to MET Tyrosine Kinase Inhibitors (2010) (0)
65 MET, the HGF receptor: Possible role in prostate cancer metastatization (2005) (0)
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial (2022) (0)
High resolution AP-MALDI MS imaging as an aid to develop new strategies to improve ALS therapy (2017) (0)
Drugs distribution assessment in solid tumor tissues : an advanced Imaging Mass Spectrometry analysis (2016) (0)
Human Cancer Biology MiR-1 DownregulationCooperateswithMACC 1 inPromoting MET Overexpression in Human Colon Cancer (2012) (0)
Abstract 3606: Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence (2015) (0)
Intro The lignan plastic inhibi (2010) (0)
Structure, Biosynthesis and Biochemical Properties of the HGF/SF Receptor (1993) (0)
Abstract A02: OXPHOS inhibition and pentose phosphate pathway induction are early events priming preneoplastic lesions toward HCC development (2016) (0)
[Pleural malignant mesothelioma in a barber: a case of atypical and indirect professional exposure to asbestos]. (2005) (0)
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach (2018) (0)
Oncogenes and tumor suppressor genes (2020) (0)
In-home supportive therapy and LD-ARA-C for high risk acute leukemic elderly patients (1994) (0)
Mechanisms of Resistance to Molecular Therapies Targeting the HGF/MET Axis (2018) (0)
Home-care treatment for selected acute leukemic elderly patients by low dose ARA-C (1993) (0)
Altered regulation of receptor associated-tyrosine kinases in human tumors (1989) (0)
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers (2020) (0)
Validation of a model of orthotopic transplantation of human gastric cancer in NOD SCID mice for generation of a gastro-esophageal patient-derived xenograft (PDX) platform to improve therapeutic outcome (2018) (0)
Clustered protocadherins methylation alterations in cancer (2019) (0)
Deregulated tyrosine kinases detected in human tumors by means of antibodies against phosphotyrosine (1989) (0)
P0317 : Down-regulation of Hao2 is associated with the onset and development of hepatocellular carcinoma in rodents (2015) (0)
881 Could antineoplastic therapy integrate palliative care for symptom relief in advanced/refractory cancer patients? (1995) (0)
The landscape of d16HER2 splice variant expression across HER2-positive cancers (2019) (0)
Reply (2011) (0)
CAN-10-1994 Cancer esearch or and Stem Cell Biology origenic and Metastatic Activity of Human Thyroid R cer Stem Cells (2010) (0)
Targeted therapies in cancer and mechanisms of resistance (2014) (0)
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. (2023) (0)
mRNA-miRNA networks identify metabolic pathways associated to the anti-tumorigenic effect of thyroid hormone on preneoplastic nodules and hepatocellular carcinoma (2022) (0)
origenic and Metastatic Activity of Human Thyroid (2010) (0)
Growth Factor Receptor (2020) (0)
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. (2023) (0)
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies (2017) (0)
miRs*: Innocent bystanders only? (2016) (0)
Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System (2022) (0)
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC (0)
HGF (Hepatocyte Growth Factor)/MET System (2003) (0)
microRNAは肝細胞癌の診断,予後予測,治療の新たなツールとなるか? (2013) (0)
Proteins phosphorylated at tyrosine residues in cells transformed by v-onc genes (1984) (0)
IMMUNOLOGICAL DETECTION OF CELLULAR TARGETS FOR V-ONC GENE CODED (1984) (0)
Abstract C92: MET amplification and overexpression sustain resistance and drive drug dependency to the DN30Fab antibody in MET-addicted cells. (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Silvia Giordano?

Silvia Giordano is affiliated with the following schools:

Silvia Giordano's Academic­Influence.com Rankings